Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1983 1
1984 1
1985 3
1986 1
1987 2
1988 5
1989 1
1990 1
1991 7
1992 2
1993 3
1994 5
1995 9
1996 4
1997 10
1998 8
1999 4
2000 4
2001 7
2002 4
2003 9
2004 16
2005 12
2006 11
2007 8
2008 8
2009 8
2010 14
2011 12
2012 14
2013 6
2014 11
2015 14
2016 13
2017 13
2018 10
2019 10
2020 18
2021 16
2022 10
2023 12
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

304 results

Results by year

Filters applied: . Clear all
Page 1
Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.
Van Mieghem NM, Unverdorben M, Hengstenberg C, Möllmann H, Mehran R, López-Otero D, Nombela-Franco L, Moreno R, Nordbeck P, Thiele H, Lang I, Zamorano JL, Shawl F, Yamamoto M, Watanabe Y, Hayashida K, Hambrecht R, Meincke F, Vranckx P, Jin J, Boersma E, Rodés-Cabau J, Ohlmann P, Capranzano P, Kim HS, Pilgrim T, Anderson R, Baber U, Duggal A, Laeis P, Lanz H, Chen C, Valgimigli M, Veltkamp R, Saito S, Dangas GD; ENVISAGE-TAVI AF Investigators. Van Mieghem NM, et al. N Engl J Med. 2021 Dec 2;385(23):2150-2160. doi: 10.1056/NEJMoa2111016. Epub 2021 Aug 28. N Engl J Med. 2021. PMID: 34449183 Clinical Trial.
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.
Rao SV, Kirsch B, Bhatt DL, Budaj A, Coppolecchia R, Eikelboom J, James SK, Jones WS, Merkely B, Keller L, Hermanides RS, Campo G, Ferreiro JL, Shibasaki T, Mundl H, Alexander JH; PACIFIC AMI Investigators. Rao SV, et al. Circulation. 2022 Oct 18;146(16):1196-1206. doi: 10.1161/CIRCULATIONAHA.122.061612. Epub 2022 Aug 27. Circulation. 2022. PMID: 36030390 Clinical Trial.
YAP regulates liver size and function.
Miyamura N, Nishina H. Miyamura N, et al. Among authors: nishina h. Cell Cycle. 2018;17(3):267-268. doi: 10.1080/15384101.2017.1407390. Epub 2018 Mar 22. Cell Cycle. 2018. PMID: 29169269 Free PMC article. No abstract available.
Stem cell challenges and opportunities.
Ite K, Toyoda M, Akiyama S, Enosawa S, Yoshioka S, Yukitake T, Yamazaki-Inoue M, Tatsumi K, Akutsu H, Nishina H, Kimura T, Otani N, Nakazawa A, Fukuda A, Kasahara M, Umezawa A. Ite K, et al. Among authors: nishina h. Prog Mol Biol Transl Sci. 2023;199:379-395. doi: 10.1016/bs.pmbts.2023.03.004. Epub 2023 Jul 26. Prog Mol Biol Transl Sci. 2023. PMID: 37678981
Hippo-TAZ signaling is the master regulator of the onset of triple-negative basal-like breast cancers.
Soyama H, Nishio M, Otani J, Sakuma T, Takao S, Hara S, Masuda T, Mimori K, Toyokuni S, Lydon JP, Nakao K, Nishina H, Fukumoto T, Maehama T, Suzuki A. Soyama H, et al. Among authors: nishina h. Proc Natl Acad Sci U S A. 2022 Jul 19;119(29):e2123134119. doi: 10.1073/pnas.2123134119. Epub 2022 Jul 11. Proc Natl Acad Sci U S A. 2022. PMID: 35858357 Free PMC article.
Development of small fluorescent probes for the analysis of autophagy kinetics.
Sakurai HT, Iwashita H, Arakawa S, Yikelamu A, Kusaba M, Kofuji S, Nishina H, Ishiyama M, Ueno Y, Shimizu S. Sakurai HT, et al. Among authors: nishina h. iScience. 2023 Jun 28;26(7):107218. doi: 10.1016/j.isci.2023.107218. eCollection 2023 Jul 21. iScience. 2023. PMID: 37456828 Free PMC article.
YAP is essential for 3D organogenesis withstanding gravity.
Asaoka Y, Nishina H, Furutani-Seiki M. Asaoka Y, et al. Among authors: nishina h. Dev Growth Differ. 2017 Jan;59(1):52-58. doi: 10.1111/dgd.12338. Epub 2017 Jan 16. Dev Growth Differ. 2017. PMID: 28093734 Review.
Collagen type I-mediated mechanotransduction controls epithelial cell fate conversion during intestinal inflammation.
Kobayashi S, Ogasawara N, Watanabe S, Yoneyama Y, Kirino S, Hiraguri Y, Inoue M, Nagata S, Okamoto-Uchida Y, Kofuji S, Shimizu H, Ito G, Mizutani T, Yamauchi S, Kinugasa Y, Kano Y, Nemoto Y, Watanabe M, Tsuchiya K, Nishina H, Okamoto R, Yui S. Kobayashi S, et al. Among authors: nishina h. Inflamm Regen. 2022 Nov 28;42(1):49. doi: 10.1186/s41232-022-00237-3. Inflamm Regen. 2022. PMID: 36443773 Free PMC article.
Deferred Versus Performed Revascularization for Left Main Coronary Disease With Hemodynamic Significance.
Warisawa T, Cook CM, Ahmad Y, Howard JP, Seligman H, Rajkumar C, Toya T, Doi S, Nakajima A, Nakayama M, Vera-Urquiza R, Yuasa S, Sato T, Kikuta Y, Kawase Y, Nishina H, Al-Lamee R, Sen S, Lerman A, Matsuo H, Akashi YJ, Escaned J, Davies JE. Warisawa T, et al. Among authors: nishina h. Circ Cardiovasc Interv. 2023 Jun;16(6):e012700. doi: 10.1161/CIRCINTERVENTIONS.122.012700. Epub 2023 Jun 20. Circ Cardiovasc Interv. 2023. PMID: 37339234 Free article.
Rationale and design of Non-antithrombotic Therapy After Transcatheter Aortic Valve Implantation (NAPT) Trial.
Inohara T, Otsuka T, Watanabe Y, Shirai S, Tada N, Yamanaka F, Ueno H, Ohno Y, Tabata M, Suzuyama H, Asami M, Yamawaki M, Izumo M, Yamasaki K, Nishina H, Fuku Y, Mizutani K, Yashima F, Yamamoto M, Hayashida K. Inohara T, et al. Among authors: nishina h. Contemp Clin Trials. 2023 Nov;134:107358. doi: 10.1016/j.cct.2023.107358. Epub 2023 Oct 16. Contemp Clin Trials. 2023. PMID: 37852534 Clinical Trial.
304 results